Search results for "double"

showing 10 items of 2879 documents

Effect of contact lens surface properties on comfort, tear stability and ocular physiology.

2018

Aim: Retrospective analysis of different contact lens wearing groups suggests lens surface lubricity is the main factor influencing contact lens comfort. However, the examined commercially available contact lenses differ in material and design as well as surface properties. Hence this study isolates the contribution of lens surface properties using an ultra-thin coating technology. Methods: Nineteen habitual contact lens wearers (21.6. ±. 1.7years) wore formofilcon B soft monthly disposable contact lenses with and without coating technology modified surface properties for a month each in a randomised double-masked cross-over study. Objective non-invasive: breakup time (NIKBUT), NIKBUT avera…

0301 basic medicineMalemedicine.medical_specialtyVisual analogue scaleSurface Propertieslaw.invention03 medical and health sciencesOcular physiologyYoung Adult0302 clinical medicineOpticsDouble-Blind MethodlawOphthalmologySurveys and QuestionnairesRetrospective analysisMedicineHumansCoefficient of frictionDisposable EquipmentRetrospective StudiesCross-Over Studiesbusiness.industryGeneral MedicineContact Lenses Hydrophiliceye diseasesLens (optics)Contact lensOphthalmology030104 developmental biologyPatient SatisfactionTears030221 ophthalmology & optometryFemalebusinessGrading scaleOptometryContact lensanterior eye : the journal of the British Contact Lens Association
researchProduct

Can a Prebiotic Formulation Reduce Frailty Levels in Older People?

2019

Objective: The purpose of this study was to examine whether a prebiotic formulation reduces frailty index (FI) levels in older people. Design: We conducted secondary analysis of a placebo-controlled, randomized, double-blind design study. Setting/Participants: The study included non-demented people over the age of 65 who were living in nursing homes and were able to walk. Fifty participants completed the study (75.3±7.3 years, 70% females). Intervention: Participants were randomly assigned to either a group who received daily Darmocare Pre® (inulin and fructooligosaccharides) for 13 weeks or a placebo group (maltodextrin). Measurement: The primary outcome in this secondary analysis was chan…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatmentFrail ElderlyFrailty IndexOligosaccharidesPlacebo grouplaw.invention03 medical and health sciencesPrimary outcomeRandomized controlled trialDouble-Blind MethodlawSecondary analysismedicineHumansAgedAged 80 and overFrailtybusiness.industryPrebioticInulinGeneral Medicine030104 developmental biologyPrebioticsTreatment OutcomePhysical therapyFemalebusinessOlder peopleNursing homesThe Journal of frailtyaging
researchProduct

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

2019

Background Time in therapeutic range (TTR) measures the quality of vitamin K antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized SAMe-TT2-R2 score (≥2 vs. < 2 points) can predict if adequate TTR is unlikely to be achieved. Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism (VTE) randomized to the warfarin arm of the Hokusai-VTE trial. Patients and Methods A total of 3,874 patients were included in the primary analysis (day 31–180 from randomization). The efficacy and safety outcomes were symptomatic recurrent VTE and major or clinically relevant non-major bleeding. Results The rates of recurrent VTE and bleeding events we…

0301 basic medicineMalevitamin K antagonistEXTERNAL VALIDATIONTime FactorsVitamin KWarfarin/therapeutic use030204 cardiovascular system & hematologyTHERAPYSeverity of Illness Indexlaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawRecurrenceAtrial FibrillationVitamin K/antagonists & inhibitorsStrokeRISKAtrial fibrillationHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedrisk assessment modelTIMEPREDICTSTreatment OutcomeAnticoagulants/therapeutic useResearch DesignANTICOAGULATION CONTROLFemaleLife Sciences & Biomedicinemedicine.drugHemorrhage/drug therapyAdultmedicine.medical_specialtyRandomizationmedicine.drug_classvenous thromboembolismHemorrhageRisk AssessmentSensitivity and SpecificityEDOXABAN03 medical and health sciencesDouble-Blind MethodVITAMIN-K ANTAGONISTSInternal medicinemedicineNONVALVULAR ATRIAL-FIBRILLATIONORAL ANTICOAGULANTHumansInternational Normalized RatioBlood CoagulationScience & Technologybusiness.industryquality of treatmentWarfarinAnticoagulantsmedicine.diseasewarfarinClinical trial030104 developmental biologyPeripheral Vascular DiseasechemistryBlood Coagulation/drug effectsAtrial Fibrillation/bloodCardiovascular System & CardiologyLinear ModelsWarfarinbusinessVenous Thromboembolism/drug therapyThrombosis and haemostasis
researchProduct

Emerging switchable ultraviolet photoluminescence in dehydrated Zn/Al layered double hydroxide nanoplatelets

2019

AbstractLayered double hydroxides show intriguing physical and chemical properties arising by their intrinsic self-assembled stacking of molecular-thick 2D nanosheets, enhanced active surface area, hosting of guest species by intercalation and anion exchanging capabilities. Here, we report on the unprecedented emerging intense ultraviolet photoluminescence in Zn/Al layered double hydroxide high-aspect-ratio nanoplatelets, which we discovered to be fully activated by drying under vacuum condition and thermal desorption as well. Photoluminescence and its quenching were reproducibly switched by a dehydration–hydration process. Photoluminescence properties were comprehensively evaluated, such a…

0301 basic medicineMaterials sciencePhotoluminescenceCoprecipitationIntercalation (chemistry)Thermal desorptionlcsh:Medicineswitchable ultraviolet photoluminescenceengineering.materialTwo-dimensional materialsArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicine2D materials Layered Double Hydroxides Photoluminescence Vacuumlcsh:ScienceQuenchingMultidisciplinaryZn/Al layered double hydroxideX-ray Diffractionlcsh:RSettore FIS/01 - Fisica SperimentaleLayered double hydroxidesExfoliation joint030104 developmental biologychemistryChemical engineeringengineeringHydroxidelcsh:Q030217 neurology & neurosurgeryScientific Reports
researchProduct

Addition of thiols to the double bond of dipeptide C-terminal dehydroalanine as a source of new inhibitors of cathepsin C.

2017

Addition of thiols to double bond of glycyl-dehydroalanine and phenyl-dehydroalanine esters provided micromolar inhibitors of cathepsin C. The structure-activity studies indicated that dipeptides containing N-terminal phenylalanine exhibit higher affinity towards the enzyme. A series of C-terminal S-substituted cysteines are responsible for varying interaction with S1 binding pocket of cathepsin C. Depending on diastereomer these compounds most likely act as slowly reacting substrates or competitive inhibitors. This was proved by TLC analysis of the medium in which interaction of methyl (S)-phenylalanyl-(R,S)-(S-adamantyl)cysteinate (7i) with the enzyme was studied. Molecular modeling enabl…

0301 basic medicineModels MolecularDouble bondStereochemistryPhenylalanineCysteine Proteinase InhibitorsBiochemistryCathepsin CCathepsin CSubstrate Specificity03 medical and health scienceschemistry.chemical_compoundStructure-Activity Relationship0302 clinical medicineDehydroalanineMoietyAnimalsSulfhydryl CompoundsBinding sitechemistry.chemical_classificationDipeptideAlanineBinding SitesDehydropeptidesDiastereomerEnzyme inhibitorsGeneral MedicineDipeptidesKinetics030104 developmental biologychemistryThiol addition030220 oncology & carcinogenesisCattleBiochimie
researchProduct

Autologous dental pulp mesenchymal stem cells for inferior third molar post-extraction socket healing : a split-mouth randomised clinical trial

2018

Background Since the discovery of adult mesenchymal stem cells extensive research has been conducted to determine their mechanisms of differentiation and effectiveness in cell therapy and regenerative medicine. Material and Methods To assess the efficacy of autologous dental pulp mesenchymal stem cells delivered in a collagen matrix for post-extraction socket healing, a single-centre, double-blind, randomised, split-mouth, controlled clinical trial was performed. Both impacted mandibular third molars were extracted from 32 patients. Dental pulp was collected and dissociated; the resulting cell suspension, obtained by centrifugation, was incorporated into a resorbable collagen matrix and imp…

0301 basic medicineMolarAdultMaleAdolescentDentistryBone healingMesenchymal Stem Cell TransplantationBone resorptionMandibular second molar03 medical and health sciencesYoung AdultDouble-Blind MethodHounsfield scaleMedicineHumansTooth SocketAutograftsGeneral DentistryDental PulpPostoperative CareWound Healingbusiness.industryResearchMesenchymal stem cellInterdental consonant:CIENCIAS MÉDICAS [UNESCO]030104 developmental biologyOtorhinolaryngologyTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryFemaleMolar ThirdOral SurgeryWound healingbusiness
researchProduct

Neural stem cells in the adult olfactory bulb core generate mature neurons in vivo.

2021

17 páginas, 7 figuras.

0301 basic medicineNeurobiologia del desenvolupamentRostral migratory streamNeurogenesisSubventricular zoneStem cellsAdult neurogenesis03 medical and health sciencesMiceOlfactory bulb0302 clinical medicineCalretininNeural Stem CellsInterneuronsmedicineAnimalsDevelopmental neurobiologyNeural stem cellsNeuronsbiologyNeurogenesisCell DifferentiationCell BiologyOlfactory BulbNeural stem cellDoublecortinCell biologyOlfactory bulb030104 developmental biologymedicine.anatomical_structurenervous systemSynapsesbiology.proteinMolecular MedicineNeuronNeuNCèl·lules mare030217 neurology & neurosurgeryDevelopmental BiologyStem cells (Dayton, Ohio)REFERENCES
researchProduct

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in pat…

2017

3539 Background: VEGF-A and ANG-2 have complementary roles in regulation of tumor angiogenesis. Targeting VEGF-A with BEV in combination chemotherapy (CT) in mCRC has proven to increase PFS and OS. ANG-2 is overexpressed and associated with poor outcome of mCRC pts receiving BEVcontaining treatment. Hence, dual blockade of VEGF-A and ANG-2 by the bispecific mAb VAN with standard CT may improve clinical activity in mCRC. Methods: All pts received mFOLFOX-6 and were randomized 1:1 to also receive intravenous VAN 2000 mg every other week (Q2W) (Arm A) or BEV 5 mg/kg Q2W (Arm B). The primary end point was investigator assessed progression-free survival (PFS). Key eligibility criteria included …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerbusiness.industryPhases of clinical researchCombination chemotherapymedicine.diseaseSurgeryDouble blind03 medical and health sciences030104 developmental biologyOncologyFOLFOXVanucizumabInternal medicinemedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gef…

2019

The management of multiple primary cancers, an event not so infrequent in oncology practice, is a critical issue due to the lack of literature. In this study, we reported the case of a patient with non-small cell metastatic lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. It achieved a progression-free survival and a28-months overall survival (OS) for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapy treatmentsshowed a good safety profile. Given the insignificant frequency …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentCellgefitinibpancreatic ductal adenocarcinomaCase Reportmedicine.disease_causechemotherapylcsh:RC254-28203 medical and health sciences0302 clinical medicineGefitinibInternal medicinemedicineLung cancerSurvival ratenon-small cell lung cancerChemotherapyMutationbusiness.industrydouble primary cancersLong Term Survivormedicine.diseaseDouble primary cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensGemcitabine030104 developmental biologymedicine.anatomical_structureOncologyB7-H3030220 oncology & carcinogenesisbusinessmedicine.drugCancers
researchProduct

Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?

2018

Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m

0301 basic medicineOncologyMaleLung NeoplasmsDNA Mutational AnalysisPoly (ADP-Ribose) Polymerase-1Placebos0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsPromoter Regions GeneticDNA Modification MethylasesAged 80 and overStandard treatmentNuclear ProteinsMiddle AgedNeoplastic Cells CirculatingImmunohistochemistryhumanitiesEditorialOncology030220 oncology & carcinogenesisFemaleNon small cellAdultmedicine.medical_specialtyMEDLINEAggressive disease03 medical and health sciencesText miningDouble-Blind MethodInternal medicinemedicineBiomarkers TumorTemozolomideHumansLung cancerneoplasmsAntineoplastic Agents AlkylatingAgedbusiness.industryTumor Suppressor ProteinsDNA Methylationmedicine.diseaseSmall Cell Lung Carcinomarespiratory tract diseases030104 developmental biologyDNA Repair EnzymesBenzimidazolesPersonalized medicinebusiness
researchProduct